The World Health Organization (WHO) announced on February 11 that Swiss pharmaceutical company Roche's anti-arthritis drug Tocilizumab has been pre-qualified for the treatment of novel coronavirus pneumonia (COVID-19).
There are three types of tocilizumab that have been included in the WHO prequalification list of new coronavirus treatments this time, and their doses are different.
Tocilizumab is a monoclonal antibody (Monoclonal antibody, also known as monoclonal antibody).
WHO added tocilizumab, a monoclonal antibody, to its list of prequalified treatments for #COVID19.
To date, six COVID-19 treatments have been prequalified by WHO, including the three presentations of the product prequalified today. More info 👉https://t .co/yKLEAXCUtu pic.twitter.com/7s0bMGCsL2
— World Health Organization (WHO) (@WHO) February 11, 2022
Some critically ill patients with new coronary pneumonia have obvious inflammatory reactions, rapid deterioration of the condition, and increasing oxygen demand.
Citing clinical studies, the WHO said that intravenous tocilizumab reduced mortality in these patients and shortened the length of hospital stay in some patients.
New Coronary Pneumonia｜3,000 government employees in New York, USA were fired for insisting on refusing vaccination ｜Multinational study: New coronavirus can destroy the placenta and cause stillbirth
The WHO recommends that tocilizumab be used only for the treatment of patients with COVID-19 who are severely or critically ill.